| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 231.10 | 64.0% | 21.3% |
| Total Income | 231.10 | 64.0% | 21.3% |
| Expenditure | 154.60 | 11.0% | 32.6% |
| PBT | 57.60 | 442.9% | 59.5% |
| Net Profit | 51.20 | 526.7% | 55.4% |
| OPM | 33.10% | 31.97pp | 11.15pp |
| NPM | 22.16% | 30.67pp | 16.92pp |
| EPS | 0.96 | 536.4% | 55.6% |
Emergent BioSolutions Reports Q3 2025: Revenues $231.1M
04 May 2026 · 4 May, 8:39 am
Summary
Emergent BioSolutions Inc. reported financial results for the third quarter ended September 30, 2025. Total revenues for Q3 2025 were $231.1 million, exceeding the high end of guidance by $21 million. Net income for the quarter was $51.2 million, with a net income margin of 22%. The company is raising its full year 2025 revenue and profitability guidance. The company secured eleven MCM contract modifications and product orders in 2025.
Key Highlights
- 1
Emergent BioSolutions reported third quarter 2025 total revenues of $231.1 million, exceeding the high end of Q3 guidance by $21.0 million.
- 2
The company's third quarter 2025 net income was $51.2 million, resulting in a net income margin of 22%.
- 3
Gross margin percentage for the third quarter 2025 was 54%, and adjusted gross margin percentage was 61%, representing an expansion of 300 bps and 200 bps, respectively, compared to the prior year.
- 4
Adjusted EBITDA for the third quarter 2025 reached $87.8 million, with an adjusted EBITDA margin of 38%.
- 5
The company secured $29 Million in MCM product orders from an international government partner.
- 6
Naloxone revenue experienced strong sequential growth, primarily driven by NARCAN® Nasal Spray, QoQ through Q3 2025.
- 7
The company is raising the full year 2025 revenue and profitability guidance.
Management Comments
Joe Papa
“Following a strong second quarter, we are proud to again beat the high end of our third quarter 2025 revenue guidance by $21 million, with continued margin expansion that gives us confidence in meeting the higher end of our adjusted EBITDA guidance for 2025. We remain confident in our products business as evidenced by the sequential growth of our naloxone franchise, where pricing has stabilized for NARCAN® Nasal Spray, as well as continued demand from our international customers, who represent 34% of our medical countermeasures orders year to date. The Company has now secured eleven MCM contract modifications and product orders in 2025, highlighting the consistent global demand for medical countermeasures products, in a world where biological threats represent a growing risk. Our balance sheet is healthy, and we are judiciously deploying our capital to create shareholder value and build a long-term growth trajectory.”
Informational and educational content only. Not investment advice.